* Review team’s questions are in line with company’s
expectations
The post BRIEF-Dynavax Technologies received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B appeared first on NASDAQ.
BRIEF-Dynavax Technologies received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B
